Skip to Main Navigation Skip to Main Content Skip to Footer

The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.

  • About Stem Cells
  • Donate
  • Join

The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.

  • About ISSCR
    • History & Philosophy
    • ISSCR Leadership
      • Officers & Board of Directors
      • ISSCR Committees
    • ISSCR Staff
    • Awards
      • Zhongmei Chen Yong Awards for Scientific Excellence
      • ISSCR Dr. Susan Lim Award for Outstanding Young Investigator
      • ISSCR Tobias Award Lecture
      • ISSCR Achievement Award
      • ISSCR Momentum Award
      • Public Service Award
      • ISSCR Award for Innovation
      • Poster Awards
      • Merit Abstract Awards
    • Circle of Stem Cell Institute and Center Directors
    • Donate
    • Contact Us
  • Membership
    • Join or Renew
    • Update Your Profile
    • Member Spotlight
    • 2021 Election
  • Meetings & Events
    • Annual Meetings
      • ISSCR Annual Meeting 2021
      • About Annual Meetings
    • International Symposia
      • About International Symposia
      • Tokyo 2021 Symposium
      • Shanghai 2022 Symposium
      • Paris 2022 Symposium
    • ISSCR Digital
      • About ISSCR Digital
      • COVID-19 Networking Meetings
      • Stem Cells and Global Sustainability
      • Computational Stem Cell Biology
      • Stem Cell-Based Embryo Models
      • Cell Manufacturing
    • Non-ISSCR Meetings & Courses
  • Policy & Advocacy
    • Guidelines
    • Lawrence Goldstein Science Policy Fellowship Program
    • Positions and Statements
    • Annual Advocacy Day
  • News & Publications
    • Stem Cell Reports
      • Journal Homepage
      • Editors
      • Editorial Board
    • ISSCR News Digital Newsletter
      • Archive
      • Advertise in ISSCR News
    • Press Releases/Statements
    • Stem Cells in Focus - Blog
    • News from ISSCR
  • Careers
    • Job Board
    • Jobs with the ISSCR
    • Career Development Videos
    • Funding Resources
    • Women in Science
  • Resources
    • Scientific Resources
    • Clinical Resources
    • Education Resources
    • Patient Resources
    • Stem Cell Institutes and Centers
    • COVID-19 Resources for the Stem Cell Community
      • Covid 19 Networking & Meetings
    • ISSCR COVID-19 Survey Results
  • Home
  • News & Publications
  • News Articles
  • Member News Items
  • Policy News
  • Press Releases/Statements
      • 14 June, 2018

    ISSCR Opposes Proposal to Restrict Fetal Tissue Research

    The ISSCR opposes the U.S. House of Representatives proposal to ban federal funding for fetal tissue research. ISSCR President Hans Clevers released a statement on the issue.
    Full story
      • 4 June, 2018

    ISSCR Responds to President Trump Signing 'Right to Try' Law

    The ISSCR is disappointed with the enactment of the ‘Right to Try’ law. Along with more than 100 patient and research groups opposing the bill, we believe it will put patients at risk and undermine the effective FDA Expanded Access Program already in place to give seriously ill patients access to experimental treatments.
    Full story
      • 10 May, 2018

    ISSCR Applauds Federal Injunctions Against Stem Cell Clinics

    The ISSCR is pleased that federal prosecutors in the U.S. have taken action to halt the marketing and delivery of unproven stem cell treatments at clinics they allege are operating outside of FDA regulation.
    Full story
      • 7 May, 2018

    Active Support for Stem Cell Research Around the World

    Scientific progress requires that legislators and regulators around the world recognize and appreciate the value of research and actively support pro-science policies. The ISSCR, through its policy program, champions the advancement of stem cell research and its translation to medicine.
    Full story
      • 26 April, 2018

    ISSCR Applauds Australia’s Move to Regulate Autologous Human Cell and Tissue Products

    The ISSCR appreciates the new framework proposed by Australia’s Therapeutic Goods Administration (TGA) for the regulation of human cell and tissue products that use a person’s own cells (‘autologous use’).
    Full story
      • 19 April, 2018

    ISSCR Advocates for Stem Cells and Basic Research in Europe

    ISSCR members and staff met 12 April with the European Parliament’s Committee on Industry, Research and Energy to advocate for investments in basic research in the European Union’s 9th Framework Programme for Research and Innovation.
    Full story
      • 3 April, 2018

    ISSCR Advocates for Science Investment in Letter to European Commission

    In a letter to the European Commission today, the ISSCR encourages the EU to spur innovation by supporting basic research and programs that foster cooperation among fundamental research endeavors across Europe.
    Full story
      • 12 March, 2018

    'Right to Try' Legislation in U.S. House of Representatives is Narrowly Defeated; ISSCR Opposed

    The legislation would have put patients at risk, slowed the development of effective stem cell therapies, and blocked the Food and Drug Administration (FDA) from access to crucial data about the safety and effectiveness of new medical treatments.
    Full story
      • 11 December, 2017

    ISSCR Announces New Policy Director, Eric Anthony

    The ISSCR has named Eric Anthony to be its new Director of Policy. Anthony served more than eight years as staff in the U.S. Congress, most recently as legislative director for Congresswoman Rosa DeLauro of Connecticut. He will join the Society in early January 2018.
    Full story
      • 17 November, 2017

    ISSCR Applauds the FDA Announcement of New Guidelines for Cellular Therapies and Cell-based Tissue Products

    The ISSCR commends the U.S. Food and Drug Administration (FDA) for reaffirming its regulatory authority over stem cell biologics and clarifying the criteria that determine which cell-based products fall under its oversight. These guidance documents will provide greater transparency for patients, medical professionals, and law enforcement authorities, about the legal status of stem cell treatments in the U.S.
    Full story
      • 4 October, 2017

    ISSCR Applauds California Bill to Assist Stem Cell Patients

    A measure signed into law 3 October in the state of California, U.S., requires clinics to inform patients if they are using stem cell interventions that have not been approved by the Food and Drug Administration (FDA). ISSCR president Hans Clevers expresses support for the measure.
    Full story
      • 31 August, 2017

    ISSCR Opposes U.S. Restrictions on Fetal Tissue, Embryonic Stem Cell Research

    The ISSCR joined with more than 60 medical, patient, and academic groups in writing a letter to the U.S. Senate to oppose prohibitions or restrictions that would further impede the use of federal funding for fetal tissue or embryonic stem cell research.
    Full story
      • 28 August, 2017

    ISSCR Responds to FDA Announcement of Enforcement Direction for Stem Cell Treatments

    The ISSCR commends the U.S. Food and Drug Administration (FDA) for its policy direction and enforcement efforts, to provide “bright lines and appropriate oversight” for regulating stem cell treatments and regenerative medicine.
    Full story
      • 6 May, 2017

    Letter to Texas House of Representatives, U.S., Opposing Legislation It Says Would Put Patients at Risk

    The ISSCR wrote to members of the Texas House of Representatives, U.S., to oppose House Bill 661, House Bill 810, and House Bill 3236, which would allow investigational agents to be sold to patients without first providing rigorous evidence of safety and efficacy. The ISSCR believes the legislation would put patients at serious risk of harm from unproven treatments.
    Full story
      • 17 March, 2017

    ISSCR Expresses Concern over FY2018 Budget Proposal in U.S.

    The FY2018 Discretionary Budget Plan put forward by the U.S. Administration includes dramatic cuts in funding for science and research programs that would threaten biomedical research and its translation into new therapies for millions of people worldwide.
    Full story
    • 1
    • 2
    • 3
    • 4 (current)
    • 5
    • 6
  • About ISSCR
    • History & Philosophy
    • ISSCR Leadership
    • ISSCR Staff
    • Awards
    • Circle of Stem Cell Institute and Center Directors
    • Donate
    • Contact Us
  • Membership
    • Join or Renew
    • Update Your Profile
    • Member Spotlight
    • 2021 Election
  • Meetings & Events
    • Annual Meetings
    • International Symposia
    • ISSCR Digital
    • Non-ISSCR Meetings & Courses
  • Policy & Advocacy
    • Guidelines
    • Lawrence Goldstein Science Policy Fellowship Program
    • Positions and Statements
    • Annual Advocacy Day
  • News & Publications
    • Stem Cell Reports
    • ISSCR News Digital Newsletter
    • Press Releases/Statements
    • Stem Cells in Focus - Blog
    • News from ISSCR
  • Careers
    • Job Board
    • Jobs with the ISSCR
    • Career Development Videos
    • Funding Resources
    • Women in Science
  • Resources
    • Scientific Resources
    • Clinical Resources
    • Education Resources
    • Patient Resources
    • Stem Cell Institutes and Centers
    • COVID-19 Resources for the Stem Cell Community
    • ISSCR COVID-19 Survey Results
Privacy Policy | Terms of Use
The International Society for Stem Cell Research | Phone: +1 (224) 592-5700 | Email: isscr@isscr.org
©2019 The International Society for Stem Cell Research. All rights reserved.

Connect with Us

  • Twitter
  • Facebook
  • LinkedIn
  • YouTube
  • LinkedIn